We aim to make cells virus-resistant by recoding human cells. This universal ultrasafe and virus-resistant cell line will be utilized for safe manufacturing of therapeutics and avoid bioreactor contamination like the Genzyme incident of 2009.
Funding
Funding Duration
July 1, 2019 - June 30, 2020
Funding level
Pilot
People
Principal Investigator
George Church
PhD
Robert Winthrop Professor of Genetics, Harvard Medical School
Co-PI
Yuting Chen
PhD
Visiting Research Fellow from SIAT, Church Lab (EXT), Harvard Medical School
Eriona Hysolli
PhD
Research Fellow in Genetics (INT), Harvard Medical School